AbbVie raised its quarterly cash dividend 5.2 percent to $1.82 per share, pairing the increase with a third-quarter earnings beat and a higher full-year profit forecast. Shareholders of record on January 15, 2027 will receive the new rate with the February 16, 2027 payment.
What the board approved
The board of directors declared the increase on October 30 alongside third-quarter results. The move lifts the annualized payout to $7.28 per share from $6.92.
| Dividend item | Detail |
|---|---|
| Previous quarterly rate | $1.73 per share |
| New quarterly rate | $1.82 per share |
| Increase | 5.2 percent |
| New annualized payout | $7.28 per share |
| Record date | January 15, 2027 |
| Payment date | February 16, 2027 |
Third-quarter results behind the raise
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3 percent from a year earlier. Adjusted earnings of $3.82 per share topped Wall Street consensus of roughly $3.74. The immunology drugs Skyrizi and Rinvoq each grew sales by more than 22 percent.
Management lifted full-year adjusted earnings guidance to a range of $13.95 to $13.99 per share, up from $13.76 to $13.96. Chief Executive Officer Robert A. Michael cited the company’s “strong outlook and significant momentum” in announcing both moves.
What the raise means for income investors
The increase marks a 14th consecutive year of higher dividends for the drugmaker. Since separating from Abbott in 2013, AbbVie has grown its quarterly payout by more than 350 percent.
The boost adds $0.36 per share annually. A retiree holding 1,000 shares will collect roughly $360 more per year, lifting total dividend income to about $7,280. At recent record-high prices, the new payout yields approximately 2.4 percent.
Cash generation supports the distribution. AbbVie produced about $14 billion in free cash flow through the first nine months of 2026, including nearly $2.7 billion in Skyrizi royalty payments, and ended September with $10.8 billion in cash.
Risks to watch
- Acquired IPR&D and milestone expenses trimmed $0.69 per share from 2026 guidance, and similar charges can recur in future quarters.
- Accounting-based payout ratios look elevated, so income investors should track free cash flow rather than GAAP earnings alone.
- Patent expirations on older products keep pressure on the pipeline to deliver replacement growth.
Income-focused investors have roughly ten weeks to buy before the January 15 record date. Buyers after that date wait until the May 2027 payment for the higher rate.
Common mistakes income investors make
Dividend increases tempt three recurring errors, and avoiding them matters more than catching a single payment date.
- Chasing the record date with a lump-sum purchase near all-time highs, which raises the cost basis to capture one quarterly payment.
- Confusing the GAAP payout ratio with actual cash coverage, when dividends are paid from free cash flow.
- Assuming every raise continues forever, when drugmaker payouts depend on pipeline execution and patent life.
- Overweighting one reliable payer and ignoring diversification across sectors, which concentrates the risk a dividend cut carries.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
